Home > Publications database > Long-term Outcomes of Helical Tomotherapy in Lymph Node-positive Breast Cancer Following Breast-conserving Surgery. > print

001     300741
005     20250502112933.0
024 7 _ |a 10.21873/anticanres.17577
|2 doi
024 7 _ |a pmid:40295057
|2 pmid
024 7 _ |a 0250-7005
|2 ISSN
024 7 _ |a 1791-7530
|2 ISSN
037 _ _ |a DKFZ-2025-00901
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zwicker, Felix
|0 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c
|b 0
|e First author
|u dkfz
245 _ _ |a Long-term Outcomes of Helical Tomotherapy in Lymph Node-positive Breast Cancer Following Breast-conserving Surgery.
260 _ _ |a Kapandriti, Attiki, Greece
|c 2025
|b International Institute of Anticancer Research
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1746175972_32
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E055#
520 _ _ |a Adjuvant radiotherapy is an integral component of the interdisciplinary curative treatment of lymph node-positive breast cancer. We investigated long-term clinical outcomes of helical tomotherapy following breast-conserving surgery.This single-center analysis included 80 female patients with breast cancer stages T1-T4 and lymph node metastasis (N1-N3) who underwent breast-conserving surgery, sentinel node biopsy, and/or axillary lymph node dissection. Patients received adjuvant fractionated radiation therapy to the whole breast and regional lymph node areas using helical tomotherapy. Boost irradiation was delivered sequentially or through the simultaneous integrated boost technique. Local control (LC), metastasis, survival, toxicity, and secondary malignancy rates were retrospectively analyzed.The mean follow-up duration was 75 months. The 5- and 8-year overall survival rates were 89.4% and 87.0%, respectively. LC rates at 5- and 8-year were 98.7%, and metastasis-free survival rates were 91.2% and 85.2%, respectively. Acute erythema occurred in 70% (Grades 1-2) and 26% (Grade 3) of patients. Ipsilateral arm lymphedema of Grade 1 and Grade 2 developed in 10% and 1.3% of the treated patients, respectively. Acute or late toxicities exceeding Grade 3 were not observed.Helical tomotherapy showed excellent long-term results and low toxicity rates as adjuvant radiotherapy in patients with lymph node-positive breast cancer. The incidence of secondary malignancies was relatively low and corresponded to the preexisting records on radiation therapy. Broader clinical implementation of helical tomotherapy could benefit patients.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Helical tomotherapy
|2 Other
650 _ 7 |a adjuvant radiotherapy
|2 Other
650 _ 7 |a lymph node-positive breast cancer
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Breast Neoplasms: radiotherapy
|2 MeSH
650 _ 2 |a Breast Neoplasms: pathology
|2 MeSH
650 _ 2 |a Breast Neoplasms: surgery
|2 MeSH
650 _ 2 |a Breast Neoplasms: mortality
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Mastectomy, Segmental
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Lymphatic Metastasis: radiotherapy
|2 MeSH
650 _ 2 |a Radiotherapy, Intensity-Modulated: methods
|2 MeSH
650 _ 2 |a Radiotherapy, Intensity-Modulated: adverse effects
|2 MeSH
650 _ 2 |a Radiotherapy, Adjuvant: adverse effects
|2 MeSH
650 _ 2 |a Radiotherapy, Adjuvant: methods
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Lymph Nodes: pathology
|2 MeSH
650 _ 2 |a Sentinel Lymph Node Biopsy
|2 MeSH
650 _ 2 |a Lymph Node Excision
|2 MeSH
700 1 _ |a Raether, Luis-Philipp
|b 1
700 1 _ |a Klepper, Rudolf
|b 2
700 1 _ |a Hauswald, Henrik
|0 P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0
|b 3
|u dkfz
700 1 _ |a Hoefel, Sebastian
|b 4
700 1 _ |a Huber, Peter
|0 P:(DE-He78)3291aaac20f3d603d96744c1f0890028
|b 5
|u dkfz
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 6
|u dkfz
700 1 _ |a Schempp, Michael
|b 7
773 _ _ |a 10.21873/anticanres.17577
|g Vol. 45, no. 5, p. 2025 - 2040
|0 PERI:(DE-600)2145376-7
|n 5
|p 2025 - 2040
|t Anticancer research
|v 45
|y 2025
|x 0250-7005
909 C O |o oai:inrepo02.dkfz.de:300741
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)3291aaac20f3d603d96744c1f0890028
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANTICANCER RES : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-10
920 1 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Molekulare Radioonkologie
|x 0
920 0 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Molekulare Radioonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E055-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21